摘要
目的评估硼替佐米联合吡柔比星治疗初治多发性骨髓瘤患者的疗效。方法选取2018年3月至2019年6月在我院住院的初治多发性骨髓瘤患者60例,按患者意愿分为研究组和对照组,每组30例。研究组患者给予硼替佐米+吡柔比星+地塞米松治疗,对照组患者给予长春新碱+吡柔比星+地塞米松治疗,治疗21d为1个疗程,两组患者均治疗4个疗程,比较两组患者的治疗效果以及不良反应发生情况。结果治疗4个疗程后,研究组患者反应良好率(83.33%)显著高于对照组(53.33%),差异有统计学意义(P<0.05)。治疗期间,研究组患者血小板减少、白细胞减少的发生率显著低于对照组,差异有统计学意义(P<0.05);两组患者的外周神经病变、胃肠道反应、乏力、皮肤疱疹的发生率比较,差异无统计学意义(P>0.05)。结论硼替佐米联合吡柔比星对初治多发性骨髓瘤患者具有较好的疗效及安全性,疗效优于采用长春新碱+吡柔比星方案治疗,具有一定的临床推广应用价值。
Objective To evaluate the efficacy of bortezomib combined with pirarubicin in treating initial treatment for mutiple myeloma.Methods Sixty patients with initial treatment for multiple myeloma hospitalized in our hospital from March 2018 to June 2019 were selected and divided into study group and control group according to their will,with 30 cases in each group.Patients in the study group were administered bortezomib+pirarubicin+dexamethasone,whereas the control group was given vincristine+pirarubicin+dexamethasone,with 21 days as a treatment course,for four treatment courses in both groups.The therapeutic effect and adverse reactions of the two groups were compared.Results After 4 courses of treatment,the response rate of the patients in the study group(83.33%)was significantly higher than that in the control group(53.33%),with statistically significant difference(P<0.05).During treatment,the incidence of thrombocytopenia and leukopenia in the study group was significantly lower than that in the control group,and the difference was statistically significant(P<0.05).There was no statistically significant difference in the incidence of peripheral neuropathy,gastrointestinal reaction,fatigue,and skin herpes between the two groups(P>0.05).Conclusion Bortezomib combined with pirarubicin has preferable efficacy and safety on initial treatment for multiple myeloma,and the efficacy is superior to the treatment of vincristine+pirarubicin,with a certain clinical promotion and application value.
作者
吕钊
张华
李虎生
冯翠
宾燕成
廖家蓓
叶光剑
Lyu Zhao;ZHANG Hua;LI Husheng;FENG Cui;BIN Yancheng;LIAO Jiabei;YE Guangjian(Red Cross Hospital of Yulin City,Yulin 537000,Guangxi,China)
出处
《内科》
2020年第2期142-145,共4页
Internal Medicine
基金
广西壮族自治区卫生和计划生育委员会自筹经费科研项目(Z20170041)。
